e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

65.22 -0.27 (-0.40%)

Streaming Delayed Price Updated: 2:42 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

December 14, 2022

Benzinga

Via Benzinga

FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate ↗

December 14, 2022

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗

October 25, 2022

The company hopes to come out next year with at least one heart-failure drug.

Via Investor's Business Daily

Where Cytokinetics Stands With Analysts ↗

October 11, 2022

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:

Via Benzinga

Analyst Ratings for Cytokinetics ↗

July 15, 2022

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Cytokinetics Stands With Analysts ↗

May 24, 2022

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗

October 03, 2022

Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...

Via Benzinga

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗

September 07, 2022

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.

Via Benzinga

Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗

September 04, 2022

The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.

Via Talk Markets

iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗

August 08, 2022

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

What 5 Analyst Ratings Have To Say About Cytokinetics ↗

August 05, 2022

Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter:

Via Benzinga

Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M ↗

August 05, 2022

Via Benzinga

Recap: Cytokinetics Q2 Earnings ↗

August 04, 2022

Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 29, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

What 5 Analyst Ratings Have To Say About Cytokinetics ↗

June 10, 2022

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗

May 22, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...

Via Talk Markets

Why Orphan Drug Designation Offers Several Benefits

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...

Via FinancialNewsMedia

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗

May 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

May 16, 2022

Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.

Via Benzinga

Cytokinetics: Q1 Earnings Insights ↗

May 04, 2022

Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated...

Via Benzinga

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients ↗

April 04, 2022

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy